Integrated Quantitative Investments LLC Invests $361,000 in GeneDx Holdings Corp. (NASDAQ:WGS)

Integrated Quantitative Investments LLC acquired a new stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS) in the fourth quarter, Holdings Channel reports. The firm acquired 4,700 shares of the company’s stock, valued at approximately $361,000.

Several other large investors also recently added to or reduced their stakes in the stock. Barclays PLC raised its stake in shares of GeneDx by 346.3% during the third quarter. Barclays PLC now owns 18,921 shares of the company’s stock valued at $803,000 after acquiring an additional 14,681 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in GeneDx during the 3rd quarter valued at $325,000. Charles Schwab Investment Management Inc. raised its position in GeneDx by 304.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock valued at $6,240,000 after purchasing an additional 110,666 shares in the last quarter. Franklin Resources Inc. purchased a new stake in shares of GeneDx in the 3rd quarter worth $301,000. Finally, Prudential Financial Inc. bought a new position in shares of GeneDx during the 4th quarter worth $7,938,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

GeneDx Price Performance

WGS opened at $80.02 on Friday. The firm has a market capitalization of $2.25 billion, a PE ratio of -40.83 and a beta of 1.91. The business’s 50-day moving average is $88.11 and its two-hundred day moving average is $75.56. GeneDx Holdings Corp. has a 1 year low of $8.63 and a 1 year high of $115.60. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.04 by $0.66. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. The firm had revenue of $95.64 million during the quarter, compared to analyst estimates of $82.24 million. Research analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on WGS. The Goldman Sachs Group upped their price objective on shares of GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 19th. TD Cowen boosted their price target on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, GeneDx presently has a consensus rating of “Moderate Buy” and a consensus target price of $72.33.

Insider Transactions at GeneDx

In other news, CFO Kevin Feeley sold 922 shares of GeneDx stock in a transaction on Monday, March 10th. The shares were sold at an average price of $94.72, for a total transaction of $87,331.84. Following the completion of the sale, the chief financial officer now directly owns 5,446 shares in the company, valued at approximately $515,845.12. The trade was a 14.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Katherine Stueland sold 51,420 shares of the company’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $94.48, for a total value of $4,858,161.60. Following the completion of the transaction, the chief executive officer now directly owns 1,720 shares in the company, valued at approximately $162,505.60. The trade was a 96.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 163,596 shares of company stock valued at $15,490,752. Corporate insiders own 27.30% of the company’s stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.